医学
磁共振弥散成像
胼胝体
放射治疗
磁共振成像
核医学
单变量分析
多元统计
多元分析
单变量
放射科
部分各向异性
内科学
病理
统计
数学
作者
Zahra Alirezaei,Alireza Amouheidari,Sajjad Iraji,Masoud Hassanpour,Seyed Hosein Hejazi,Fariba Davanian,Mohammad Nami,Sedighe Rastaghi,Parvaneh Shokrani,Christina Tsien,Mohammad-Reza Nazem-Zadeh
标识
DOI:10.1007/s12031-023-02136-9
摘要
The aim of this study was to design a predictive radiobiological model of normal brain tissue in low-grade glioma following radiotherapy based on imaging and molecular biomarkers. Fifteen patients with primary brain tumors prospectively participated in this study and underwent radiation therapy. Magnetic resonance imaging (MRI) was obtained from the patients, including T1- and T2-weighted imaging and diffusion tensor imaging (DTI), and a generalized equivalent dose (gEUD) was calculated. The radiobiological model of the normal tissue complication probability (NTCP) was performed using the variables gEUD; axial diffusivity (AD) and radial diffusivity (RD) of the corpus callosum; and serum protein S100B by univariate and multivariate logistic regression XLIIIrd Sir Peter Freyer Memorial Lecture and Surgical Symposium (2018). Changes in AD, RD, and S100B from baseline up to the 6 months after treatment had an increasing trend and were significant in some time points (P-value < 0.05). The model resulting from RD changes in the 6 months after treatment was significantly more predictable of necrosis than other univariate models. The bivariate model combining RD changes in Gy40 dose-volume and gEUD, as well as the trivariate model obtained using gEUD, RD, and S100B, had a higher predictive value among multivariate models at the sixth month of the treatment. Changes in RD diffusion indices and in serum protein S100B value were used in the early-delayed stage as reliable biomarkers for predicting late-delayed damage (necrosis) caused by radiation in the corpus callosum. Current findings could pave the way for intervention therapies to delay the severity of damage to white matter structures, minimize cognitive impairment, and improve the quality of life of patients with low-grade glioma.
科研通智能强力驱动
Strongly Powered by AbleSci AI